incruse ellipta (previously incruse)
glaxosmithkline (ireland) limited - umeclidinium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).,
rolufta ellipta (previously rolufta)
glaxosmithkline trading services limited - umeclidinium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - rolufta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).,
incruse ellipta 55microgramsdose dry powder inhaler
glaxosmithkline uk ltd - umeclidinium bromide - inhalation powder - 65microgram/1dose
incruse ellipta 55 mcg
glaxo smith kline (israel) ltd - umeclidinium as bromide - powder for inhalation - umeclidinium as bromide 55 mcg - umeclidinium bromide - incruse is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).
incruse ellipta powder
glaxosmithkline inc - umeclidinium (umeclidinium bromide) - powder - 62.5mcg - umeclidinium (umeclidinium bromide) 62.5mcg - antimuscarinics antispasmodics
incruse ellipta powder for inhalation
glaxo operations uk ltd - umeclidinium (umeclidinium bromide) - powder for inhalation - 62.5mcg/dose
incruse ellipta inhalation powder 62.5 mcgdose
glaxosmithkline pte ltd - umeclidinium bromide 74.2 mcg (micronised) eqv. umeclidinium - powder, metered - umeclidinium bromide 74.2 mcg (micronised) eqv. umeclidinium 62.5 mcg/dose
incruse ellipta
glaxosmithkline nz limited - umeclidinium bromide 74.2ug equivalent to umeclidinium 62.5 mcg; - powder for inhalation - 62.5 mcg - active: umeclidinium bromide 74.2ug equivalent to umeclidinium 62.5 mcg excipient: lactose monohydrate magnesium stearate - incruse ellipta is indicated as a long-term once daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).